110 related articles for article (PubMed ID: 27733203)
1. Pre-treatment minority HIV-1 drug resistance mutations and long term virological outcomes: is prediction possible?
Mzingwane ML; Tiemessen CT; Richter KL; Mayaphi SH; Hunt G; Bowyer SM
Virol J; 2016 Oct; 13(1):170. PubMed ID: 27733203
[TBL] [Abstract][Full Text] [Related]
2. Human Immunodeficiency Virus-1 Drug Resistance Mutations in Iranian Treatment-experienced Individuals.
Bokharaei-Salim F; Khanaliha K; Monavari SH; Kiani SJ; Tavakoli A; Jafari E; Chavoshpour S; Razizadeh MH; Kalantari S
Curr HIV Res; 2024; 22(1):53-64. PubMed ID: 38310469
[TBL] [Abstract][Full Text] [Related]
3. Virological failure, HIV-1 drug resistance, and early mortality in adults admitted to hospital in Malawi: an observational cohort study.
Gupta-Wright A; Fielding K; van Oosterhout JJ; Alufandika M; Grint DJ; Chimbayo E; Heaney J; Byott M; Nastouli E; Mwandumba HC; Corbett EL; Gupta RK
Lancet HIV; 2020 Sep; 7(9):e620-e628. PubMed ID: 32890497
[TBL] [Abstract][Full Text] [Related]
4. Heavily treatment-experienced persons living with HIV currently in care in Italy: characteristics, risk factors, and therapeutic options-the ICONA Foundation cohort study.
Lo Caputo S; Poliseno M; Tavelli A; Gagliardini R; Rusconi S; Lapadula G; Antinori A; Francisci D; Sarmati L; Gori A; Spagnuolo V; Ceccherini-Silberstein F; d'Arminio Monforte A; Cozzi-Lepri A;
Int J Infect Dis; 2024 Jun; 143():106956. PubMed ID: 38447754
[TBL] [Abstract][Full Text] [Related]
5. The association between HIV pretreatment drug resistance and virological outcomes in children and adults in sub-Saharan Africa: A systematic review and meta-analysis.
Takem EN; Coox C; Shang J; Ndongmo C; Dokubo EK
PLoS One; 2024; 19(4):e0300456. PubMed ID: 38626183
[TBL] [Abstract][Full Text] [Related]
6. Risk of virological failure after drug burden reduction in people with 4-class drug-resistant HIV on virological suppression: A retrospective cohort analysis of data from the PRESTIGIO Registry.
Clemente T; Diotallevi S; Lolatto R; Gagliardini R; Giacomelli A; Fiscon M; Ferrara M; Cervo A; Calza L; Maggiolo F; Rusconi S; Santoro MM; Castagna A; Spagnuolo V;
Int J Antimicrob Agents; 2024 Jul; 64(1):107195. PubMed ID: 38734216
[No Abstract] [Full Text] [Related]
7. Epidemiologic and viral predictors of antiretroviral drug resistance among persons living with HIV in a large treatment program in Nigeria.
Ekong E; Ndembi N; Okonkwo P; Dakum P; Idoko J; Banigbe B; Okuma J; Agaba P; Blattner W; Adebamowo C; Charurat M
AIDS Res Ther; 2020 Feb; 17(1):7. PubMed ID: 32066473
[TBL] [Abstract][Full Text] [Related]
8. Changing how the third 95 is counted: suitable indicators for measuring U = U with findings from Taiwan.
Huang HY; Huang YC; Lo HY; Chan PC; Lee CC
AIDS Res Ther; 2024 Jun; 21(1):41. PubMed ID: 38902777
[TBL] [Abstract][Full Text] [Related]
9. Two cases of possible transmitted drug-resistant HIV: likely HIV superinfection and unmasking of pre-existing resistance.
Martin F; Lee J; Thomson E; Tarrant N; Hale A; Lacey CJ
Int J STD AIDS; 2016 Jan; 27(1):66-9. PubMed ID: 25663247
[TBL] [Abstract][Full Text] [Related]
10. Qualitative and quantitative HIV antibodies and viral reservoir size characterization in vertically infected children with virological suppression.
Brice J; Sylla M; Sayon S; Telly F; Bocar-Fofana D; Murphy R; Lambert-Niclot S; Todesco E; Grude M; Barin F; Diallo S; Pillay D; Derache A; Calvez V; Marcelin AG; Maiga AI
J Antimicrob Chemother; 2017 Apr; 72(4):1147-1151. PubMed ID: 28039275
[TBL] [Abstract][Full Text] [Related]
11. MicroRNA Expression Levels in Peripheral Blood Mononuclear Cells from Human Immunodeficiency Virus Type 1 Positive Individuals and Relationship with Different Levels of Viral Suppression.
Di Carlo D; Falasca F; Mazzuti L; Guerrizio G; Migliara G; Santori M; Lazzaro A; Mezzaroma I; D'Ettorre G; Fimiani C; Iaiani G; Antonelli G; Turriziani O
AIDS Res Hum Retroviruses; 2024 May; 40(5):321-329. PubMed ID: 37523231
[TBL] [Abstract][Full Text] [Related]
12. Non-suppressible viraemia during HIV-1 therapy: a challenge for clinicians.
Esteban-Cantos A; Montejano R; Pinto-Martínez A; Rodríguez-Centeno J; Pulido F; Arribas JR
Lancet HIV; 2024 May; 11(5):e333-e340. PubMed ID: 38604202
[TBL] [Abstract][Full Text] [Related]
13. Virological outcomes of third-line antiretroviral therapy in a global context: a systematic reviews and meta-analysis.
Kitaw TA; Abate BB; Yilak G; Tilahun BD; Faris AM; Walle GT; Haile RN
AIDS Res Ther; 2024 Jun; 21(1):43. PubMed ID: 38918866
[TBL] [Abstract][Full Text] [Related]
14. The emergence of drug resistant HIV variants and novel anti-retroviral therapy.
Paydary K; Khaghani P; Emamzadeh-Fard S; Alinaghi SA; Baesi K
Asian Pac J Trop Biomed; 2013 Jul; 3(7):515-22. PubMed ID: 23835806
[TBL] [Abstract][Full Text] [Related]
15. The HIV care cascade: a systematic review of data sources, methodology and comparability.
Medland NA; McMahon JH; Chow EP; Elliott JH; Hoy JF; Fairley CK
J Int AIDS Soc; 2015; 18(1):20634. PubMed ID: 26626715
[TBL] [Abstract][Full Text] [Related]
16. Incorporating temporal dynamics of mutations to enhance the prediction capability of antiretroviral therapy's outcome for HIV-1.
Di Teodoro G; Pirkl M; Incardona F; Vicenti I; Sönnerborg A; Kaiser R; Palagi L; Zazzi M; Lengauer T
Bioinformatics; 2024 Jun; 40(6):. PubMed ID: 38775719
[TBL] [Abstract][Full Text] [Related]
17. Detectable Virological Load and Associated Factors among People Living with HIV on Antiretroviral Treatment: A Retrospective Study.
Congedo P; Sedile R; Guido M; Banchelli F; Zizza A
Pathogens; 2024 Apr; 13(5):. PubMed ID: 38787211
[TBL] [Abstract][Full Text] [Related]
18. Understanding patterns of HIV multi-drug resistance through models of temporal and spatial drug heterogeneity.
Feder AF; Harper KN; Brumme CJ; Pennings PS
Elife; 2021 Sep; 10():. PubMed ID: 34473060
[TBL] [Abstract][Full Text] [Related]
19. Potential impact of a free online HIV treatment response prediction system for reducing virological failures and drug costs after antiretroviral therapy failure in a resource-limited setting.
Revell AD; Alvarez-Uria G; Wang D; Pozniak A; Montaner JS; Lane HC; Larder BA
Biomed Res Int; 2013; 2013():579741. PubMed ID: 24175292
[TBL] [Abstract][Full Text] [Related]
20. Seemingly Unrelated Regression Analysis of the Cost and Health-Related Quality of Life Outcomes of the REVAMP Randomized Clinical Trial.
Rautenberg TA; Ng SK; George G; Moosa MS; McCluskey SM; Gilbert RF; Pillay S; Aturinda I; Ard KL; Muyindike W; Musinguzi N; Masette G; Pillay M; Moodley P; Brijkumar J; Gandhi RT; Johnson B; Sunpath H; Bwana MB; Marconi VC; Siedner MJ
Value Health Reg Issues; 2023 May; 35():42-47. PubMed ID: 36863066
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
